Press Releases Sandoz Group AG

Equities

SDZ

CH1243598427

Market Closed - Swiss Exchange Other stock markets 11:30:20 2024-06-21 EDT			5-day change	1st Jan Change
32.78 ^CHF	-0.49%		+2.79%	+21.14%

06-14	Sandoz AG Re-Submits the Biosimilar Drug EG12014 (Trastuzumab Biosimilar) 150 Mg Powder BLA to the US FDA	CI
06-07	AbbVie's tight grip on Humira market raises concerns about biosimilars	RE

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	06-10	AQ
European Biosimilar Regulatory Update	06-10	AQ
Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio	06-05	AQ
Fresenius Kabi Announces FDA Acceptance Of ABLA For Prolia® / Xgeva® (Denosumab) Biosimilar Candidate FKS518	05-31	AQ
Sandoz receives European Commission approval for Wyost and Jubbonti, the first and only biosimilars of denosumab in Europe	05-23	AQ
European Commission grants first-of-a-kind biosimilar approval	05-22	AQ
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe	05-22	GL
Sandoz reports first quarter 2024 sales	05-07	GL
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG	04-30	GL
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars	04-30	GL
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering	04-22	GL
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines	03-21	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	03-13	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	03-13	AQ
Sandoz receives FDA approval for first and only denosumab biosimilars	03-05	GL
Sandoz announces nominations to the Board of Directors and leadership change	03-05	GL
Sandoz announces nominations to the Board of Directors and leadership change	03-05	AQ
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	03-04	GL
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	03-04	AQ
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs	02-29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANDOZ : Sandoz’s improvements are worth betting on

May 08, 2024 at 08:08 am